Upadacitinib for the Management of Severe Alopecia Areata in Adolescent Patients: A Single-Centre Retrospective Study

August 2024 in “ Clinical and Experimental Dermatology ”

Vincenzo Picone, Paola Nappa, Maddalena Napolitano, Maria Giovanna Vastarella, Cataldo Patruno, Mariateresa Cantelli

Studysummary In this retrospective study conducted at a trichology clinic, the off-label use of upadacitinib for at least 24 weeks was found to have a promising efficacy and safety profile for treating severe alopecia areata in adolescents. Our plain-language summary of this paper — not a Tressless recommendation.

This retrospective single-centre study evaluated the use of upadacitinib in 15 adolescent patients (aged 12–17) with severe alopecia areata over a period of at least 24 weeks. Conducted at the University Federico II of Naples, the study found that upadacitinib shows promising efficacy and safety for treating severe alopecia areata in this age group.

View this study on doi.org →

Discuss this study in the Community →

Research cited in this study

2 / 2 results

research Upadacitinib for Management of Recalcitrant Alopecia Areata: A Retrospective Case Series

3 citations , March 2023 in “JAAD case reports”

This study describes three cases where patients with recalcitrant alopecia areata achieved complete hair regrowth on the scalp after treatment with upadacitinib, suggesting it may be beneficial for similar cases, especially those with comorbid atopic dermatitis.

research An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata

40 citations , August 2022 in “Frontiers in immunology”

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.